DrugPatentWatch Database Preview

Details for Patent: 8,536,150

« Back to Dashboard

Which drugs does patent 8,536,150 protect, and when does it expire?

Patent 8,536,150 protects LEXISCAN and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 8,536,150

Title:	Methods of myocardial perfusion imaging
Abstract:	The present invention provides a method of myocardial perfusion imaging using reduced doses of (1-{9-[(4S,2R,3R,5R)3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopu- rin-2-yl}pyrazol-4-yl)-N-methylcarboxamide.
Inventor(s):	Belardinelli; Luiz (Palo Alto, CA), Blackburn; Brent K. (Los Altos, CA), Gao; Zhenhai (San Jose, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	13/525,223
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 8,536,150
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 8,536,150

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008		RX	Yes	Yes						METHOD OF MYOCARDIAL IMAGING

International Family Members for US Patent 8,536,150

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3866501
Canada	2439222
Canada	2671940
World Intellectual Property Organization (WIPO)	0162979